CN102114185A - Medicament for treating insulin resistance of type 2 diabetes - Google Patents
Medicament for treating insulin resistance of type 2 diabetes Download PDFInfo
- Publication number
- CN102114185A CN102114185A CN2011100488897A CN201110048889A CN102114185A CN 102114185 A CN102114185 A CN 102114185A CN 2011100488897 A CN2011100488897 A CN 2011100488897A CN 201110048889 A CN201110048889 A CN 201110048889A CN 102114185 A CN102114185 A CN 102114185A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- type
- diabetes
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicament for treating insulin resistance of type 2 diabetes. Active constituents of the medicament are obtained by the steps of taking 30-40 parts of astragalus root, 15-20 parts of polygonatum, 14-18 parts of coptsir root, 15-20 parts of winged euonymus twig and 10-15 parts of silkworm moth cocoon as pharmaceutical materials, smashing half parts by weight of the astragalus root into fine powder, decocting the other pharmaceutical materials and the remaining astragalus root three times by adding water, concentrating a decoction liquid into thick paste with relative density of 1.26-1.33, adding the fine powder of the astragalus root into the thick paste, and uniformly mixing. According to a pharmacodynamic test and a clinical test, the medicament disclosed by the invention has effects of invigorating qi, nourishing yin, activating blood circulation and dissipating blood stasis and can be used for improving the insulin resistance, reducing blood sugar, correcting metabolic disorder, relieving unpleasant symptoms and improving life quality, thereby being an effective medicament for treating the insulin resistance of the type 2 diabetes.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of the type 2 diabetes mellitus insulin resistant, particularly relating to a kind of is the medicine of the treatment type 2 diabetes mellitus insulin resistant of crude drug preparation with Chinese medicine.
Background technology
Insulin resistant is meant that insulin carries out the effect deficiency of its normal biological agent, show as peripheral tissues especially muscle, fatty tissue to the obstacle that utilizes of glucose.Early stage beta Cell of islet still can compensatory ground increases insulin secretion remedying its effect deficiency, but in the course of time, the function of beta Cell of islet can be progressively depleted, causes the generation of impaired glucose tolerance and diabetes.Insulin resistant is the main pathogenesis of type 2 diabetes mellitus, also is the common peril factor of multiple diseases such as obesity, hypertension, coronary heart disease and cerebrovascular, for body brings very severe impairment.Therefore, prevention and treatment insulin resistant state have crucial meaning for the generation development that delays type 2 diabetes mellitus.
The main medicine that improves insulin resistant at present is thiazolidinediones euglycemic agent (rosiglitazone, a pioglitazone), by peroxide activator enzyme paraphyte activated receptor transcription factor, increase the glucose uptake of muscle insulin-mediated, reduce insulin resistant; Stimulate the release of fatty tissue adiponectin, increase the insulin sensitivity of liver; Leptin, phylaxin, tumor necrosis factor are reduced, improve insulin resistant.When clinical practice thiazolidinediones medicine improves insulin resistant, exist the contradiction in the treatment: increasing insulin sensitivity, when improving insulin resistant liver function, kidney merit are had certain damage, increase the heart failure probability.
In recent years it is increasing that Chinese medicine improves the research of insulin resistant, has many tangible advantages.The Chinese traditional treatment insulin resistant is not limited to a certain dirty or a certain internal organs or a certain meridians, but from integral body, determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs.Execute and singly do not give tonify deficiency when controlling, double simultaneously giving got rid of evils, and reaches reinforcement and elimination in combination, takes into account the purpose of specimen emergency.The treatment by Chinese herbs insulin resistant has a extensive future, but still exists quite not enough at present: Chinese medicine compound research lacks extensive clinical research, does not meet clinical evidence-based medicine EBM requirement, and credibility has to be strengthened; Lack with euglycemic agent and compare research, degradation under the cogency.Therefore to improve the insulin resistant Study on Mechanism extremely urgent for Chinese medicine.
Summary of the invention
The purpose of this invention is to provide a kind of medicine for the treatment of the type 2 diabetes mellitus insulin resistant, this medicine supplementing QI and nourishing YIN, activating blood circulation to eliminate turbid, it is remarkable to be used for type 2 diabetes mellitus insulin resistant effect.
Etiology and pathogenesis to the type 2 diabetes mellitus insulin resistant is studied, and sums up the type 2 diabetes mellitus insulin resistant and mostly is deficiency of both QI and YIN, the turbid mutual knot card of the stasis of blood.In quenching one's thirst, turbid generation is that it is uncomfortable to cause mechanism of qi because of " diet suffering forfeit one's integrity ", and the metabolism of water paddy is not normal, and indigestion is precise and tiny and anti-giving birth to stopped up the gas that stagnates, and stops up the interior blood stasis branch of the gas that stagnates and forms turbid.How turbid based on the stasis of blood merely commitment is, and and then in accumulate heat-transformation, the consumption cloudy Tianjin of bromhidrosis blood of hurting sb.'s feelings.Along with advancing of disease, not only consume impairment of QI the moon, also can in impairing the lung spleen kidney and the stasis of blood of regenerating is turbid.Its generation is an incremental process, produces gradually along with the progress of the state of an illness and assembles, and both reciprocal causations form vicious cycle.
At the above-mentioned pattern of syndrome characteristics of type 2 diabetes mellitus insulin resistant, the medicine of treatment type 2 diabetes mellitus insulin resistant provided by the invention is that the crude drug by following parts by weight prepares: 30～40 parts of the Radixs Astragali, 15～20 parts of Rhizoma Polygonatis, 14～18 parts of Rhizoma Coptidis, 15～20 parts of Ramulus Euonymis, 10～15 parts of Bombyx bombycis.
More than the selection and the consumption of various crude drug be that the inventor draws through groping in a large number to sum up, facts have proved that various crude drug all have curative effect preferably in above-mentioned weight range.
The conventional method of Chinese medicine preparation can be adopted, above-mentioned raw materials medicine of the present invention is prepared into conventional peroral dosage form on any pharmaceutics, but these dosage forms protection scope of the present invention can not be used to limit.It is emphasized that before any dosage form of preparation, all need to prepare earlier the active component of medicine of the present invention.
The concrete preparation method of above-mentioned each crude drug being made medicine activity component of the present invention may further comprise the steps:
A) astragalus membranaceus powder with described 1/2 parts by weight is broken into fine powder, and is standby;
B) get other crude drug and remain the Radix Astragali of 1/2 parts by weight, decoct with water three times, collecting decoction filters, and it is 1.26～1.33(60～85 ℃ that filtrate is condensed into relative density) thick paste;
C) in thick paste, add above-mentioned Radix Astragali fine powder, mix homogeneously, drying is pulverized, and obtains medicine activity component of the present invention.
Wherein, when decocting with water medicine in the step b), each amount of water is 8～10 times of weight of medicine, decocts 1～2h.
The active component of medicine of the present invention can be prepared into any peroral dosage form commonly used with the method for Chinese medicinal of routine, as pill, tablet, capsule, granule etc.
In the medicine of the present invention, the sweet tepor of the Radix Astragali is returned the spleen lung meridian, the gas of kind tonifying the lung, spleen, and lung qi can be regulated water liquid enough, makes body fluid four cloth; Temper is prosperous, and to fail water distribution paddy precise and tiny, and the Radix Astragali has QI invigorating to promote the merit of running, can make the strong fortune of taste, makes life turbid passive.The Rhizoma Polygonati nature and flavor are sweet flat, strengthening the spleen invigorating middle warmer, invigorating the spleen and benefiting QI.The Rhizoma Coptidis bitter cold, dampnessization is turbid.The Ramulus Euonymi bitter cold, activating blood circulation to eliminate turbid.Bombyx bombycis is sweet in flavor and warm in property, and quenching the thirst is turbid.All medicines share, supplementing QI and nourishing YIN, activating blood circulation to eliminate turbid, and reinforcement and elimination in combination makes deficiency in origin multiple, and mark is real dispels, and it is remarkable to be used for the treatment of type 2 diabetes mellitus insulin resistant effect.
Prove that through the test of pesticide effectiveness and clinical experimental study pharmaceutical preparation of the present invention both can improve insulin resistant, blood sugar lowering is corrected metabolism disorder, can alleviate malaise symptoms again, improves the quality of living.And pharmaceutical preparation of the present invention is cheap, and untoward reaction is few, and taking convenience is the active drug of treatment type 2 diabetes mellitus insulin resistant, has exploitation, promotional value.
The specific embodiment
Embodiment 1
It is standby that Radix Astragali 210g is ground into fine powder.Get Radix Astragali 210g, Rhizoma Polygonati 210g, Bombyx bombycis 140g, Ramulus Euonymi 210g, Rhizoma Coptidis 168g, add water 7.5Kg, decoct 1.5h.Repeat above-mentioned steps three times, collecting decoction filters, and filtrate is condensed into relative density 1.28(85 ℃) thick paste, add Radix Astragali fine powder, mixing, drying is pulverized, and incapsulates, and makes the turbid capsule of capsule QI invigoratingization.
Embodiment 2
It is standby that Radix Astragali 150g is ground into fine powder.Get Radix Astragali 150g, Rhizoma Polygonati 200g, Bombyx bombycis 150g, Ramulus Euonymi 150g, Rhizoma Coptidis 150g, add water 6.4Kg, decoct 2h.Repeat above-mentioned steps three times, collecting decoction filters, and filtrate is condensed into relative density 1.30(60 ℃) thick paste, add Radix Astragali fine powder, mixing, drying is pulverized, and adds appropriate amount of auxiliary materials, mixing is made granule, is pressed into tablet.
Embodiment 3
It is standby that Radix Astragali 210g is ground into fine powder.Get Radix Astragali 210g, Rhizoma Polygonati 200g, Bombyx bombycis 150g, Ramulus Euonymi 200g, Rhizoma Coptidis 150g, add water 9.1Kg, decoct 1h.Repeat above-mentioned steps three times, collecting decoction filters, and filtrate is condensed into relative density 1.32(85 ℃) thick paste, add Radix Astragali fine powder, mixing, drying is pulverized, and adds appropriate amount of auxiliary materials, mixing is made concentrated pill, drying, polishing.
Embodiment 4
It is standby that Radix Astragali 150g is ground into fine powder.Get Radix Astragali 150g, Rhizoma Polygonati 210g, Bombyx bombycis 100g, Ramulus Euonymi 200g, Rhizoma Coptidis 140g, add water 7.2Kg, decoct 1.5h.Repeat above-mentioned steps three times, collecting decoction filters, and filtrate is condensed into relative density 1.30(85 ℃) thick paste, add Radix Astragali fine powder, mixing, drying is pulverized, and adds appropriate amount of auxiliary materials, mixing is made granule, drying.
Embodiment 5: the turbid capsule of QI invigoratingization is to the influence of the spontaneous diabetic mice of kk-Ay.
Select 34 of the spontaneous diabetic mices of qualified kk-Ay, female, be divided into totally 5 groups of dosage in model contrast, positive control, the turbid capsule in high dose of QI invigoratingization, the turbid capsule of QI invigoratingization, the turbid capsule low dosages of QI invigoratingization at random.Each organizes mouse stomach 10% glucose solution, 20ml/kgd; Positive controls is irritated gastric hydrochloric acid metformin enteric coatel tablets 0.25g/kg.d, is equivalent to 10 times of clinical consumptions; The turbid capsule in high dose group of QI invigoratingization 3.0g/kgd, middle dosage group 1.5g/kgd, low dose group 0.75g/kgd are equivalent to 30 times, 15 times, 7.5 times of clinical consumption respectively.Model control group gives the equivalent normal saline, gastric infusion, 20ml/kg, every day 1 time, continuous 15 days.
After the administration 15 days, fasting 6 hours, the vena orbitalis posterior clump is got blood, and mice is put to death in the cervical vertebra dislocation, and 2500rpm is centrifugal, gets serum, and determination of glucose oxidase is serum glucose, chemiluminescence determination empty stomach serum insulin on an empty stomach; Get the about 100mg of mice quadriceps femoris, adding an amount of normal saline, to make 10% homogenate standby, and anthrone method is measured muscle glycogen content (mg/100g tissue) and immune enzyme linked immunosorbent assay mensuration islets of langerhans receptor β.Insulin sensitivity index (ISI)=LN[1/Fin * FBG]; Steady-state model insulin resistance index (HOMA-IR)=LN[Fin * FBG/22.5] (Fin is a fasting insulin, and FBG is a fasting glucose).
1, the turbid capsule of QI invigoratingization is to the influence of the spontaneous diabetic mice body weight of kk-Ay.
Each organizes before the administration body weight and model control group there are no significant difference; Before the model control group body weight is significantly higher than administration after the administration, before body weight significantly is lower than administration after the administration of the middle and high dosage group of the turbid capsule of QI invigoratingization (
P＜0.05,
P＜0.01); Basic, normal, high dosage group administration forebody-afterbody method of double differences value all significantly be lower than model control group (
P＜0.05,
P＜0.05,
P＜0.01), concrete outcome sees Table 1.
2, the turbid capsule of QI invigoratingization is to the influence of the spontaneous blood glucose in diabetic mice of kk-Ay.
Model is respectively organized the mice fasting glucose and is significantly higher than model control group before the administration; After the administration with administration before the basic, normal, high dosage group of the turbid capsule of fasting glucose difference QI invigoratingization all be significantly higher than model control group (
P＜0.05,
P＜0.05,
P＜0.01).
Show that the basic, normal, high dosage group of the turbid capsule of QI invigoratingization all significantly reduces the spontaneous blood glucose in diabetic mice of kk-Ay.
3, the turbid capsule of QI invigoratingization is to the influence of the spontaneous diabetic mice insulin sensitivity of kk-Ay.
The basic, normal, high dosage group of the turbid capsule of QI invigoratingization fasting insulin level significantly be lower than model control group (
P＜0.05,
P＜0.05,
P＜0.01); Insulin sensitivity index be significantly higher than model control group (
P＜0.05,
P＜0.01,
P＜0.01); Insulin resistance index significantly be lower than model control group (
P＜0.05,
P＜0.01,
P＜0.01).See table 3 for details.
Show that the turbid capsule of QI invigoratingization significantly improves the spontaneous diabetic mice insulin sensitivity index of kk-Ay, reduce insulin resistance index, the spontaneous diabetic mice of kk-Ay is had the insulin sensitivity of increasing effect.
4, the turbid capsule of QI invigoratingization is to the influence of the little islets of langerhans beta receptor of the spontaneous diabetes of kk-Ay Insulin receptor INSR number.
The basic, normal, high dosage group of the turbid capsule of QI invigoratingization islets of langerhans beta receptor content all be significantly higher than model control group (
P＜0.05,
P＜0.01,
P＜0.01), show that the turbid capsule of QI invigoratingization can significantly improve the spontaneous diabetic mice islets of langerhans of kk-Ay beta receptor content, its sensitization reaches by increasing the Insulin receptor INSR number.
Embodiment 6: the turbid capsule of QI invigoratingization is to the hypoglycemic activity of alloxan diabetes mice.
Get 60 of mices, female, hero half and half is divided into totally 6 groups of dosage in normal control, model contrast, positive control, the turbid capsule in high dose of QI invigoratingization, the turbid capsule of QI invigoratingization, the turbid capsule low dosages of QI invigoratingization, 10 every group at random.Except that the normal control group, all the other are respectively organized the mouse tail vein injection alloxan and make the alloxan diabetes model.Each organizes mouse stomach 10% glucose solution, 20ml/kgd; Positive controls is irritated gastric hydrochloric acid metformin enteric coatel tablets 0.25g/kg.d; The turbid capsule in high dose group of QI invigoratingization 3.0g/kgd, middle dosage group 1.5g/kgd, low dose group 0.75g/kgd, normal control group, model control group give the equivalent normal saline, gastric infusion, 20ml/kg, every day 1 time, continuous 15 days.Observe the influence of the turbid capsule of QI invigoratingization to the alloxan diabetes mice, the alloxan diabetes mouse blood sugar is significantly higher than the normal control group, and the basic, normal, high dosage of the turbid capsule of QI invigoratingization all significantly reduces the alloxan diabetes mouse blood sugar.
Embodiment 7
Select Shanxi Province's institute of traditional Chinese medicine's department of endocrinology outpatient service and inpatient, meet the diagnostic criteria of type 2 diabetes mellitus insulin resistant, meet simultaneously deficiency of both QI and YIN again, the turbid mutual knot of the stasis of blood is demonstrate,proved dialectical standard person's 60 examples, be divided into turbid capsule for treating group of QI invigoratingization and pioglitazone hydrochloride matched group at random, wherein 30 examples are organized in treatment, matched group 30 examples, treated for 12 weeks, observe treatment front and back tcm syndrome, blood glucose, blood fat, insulin sensitivity sex index, safety indexes.
Make a definite diagnosis diabetes: according to WHO diabetes diagnosis standard in 1999, have diabetic symptom, and meet one of following condition person, get final product diagnosing diabetes: fasting glucose 〉=7.0mmol; 2 hours after the meal blood glucose 〉=11.1mmol; Blood glucose 〉=11.1mmol behind the oral 75g glucose.
The anti-diagnostic criteria of supporting of type 2 diabetes mellitus insulin: formulate with reference to the related content in " insulin resistance syndrome ", promptly meet above diabetes diagnosis standard, insulin sensitivity is reduced, and serum insulin concentration is normal or the person of increasing.
Tcm diagnosis standard: with reference to the quench one's thirst related content of " the dialectical by stages and efficacy assessment standard of diabetes (DM) traditional Chinese medical science " that Professional Committee formulates of treatment diabetes (diabetes) the clinical research guideline of the new Chinese medicine in " new Chinese medicine clinical research guideline " and Chinese Chinese medicine association internal medicine, work out following standard: fatigue and weakness, the lazyness of breathing hard speech, body is fat partially, sticky not well or xerostomia feeling thirst but no desire to drink in mouthful, dizzy, abdominal distension and anorexia, limbs are aching and limp, nervous uncomfortable in chest, corpulent tongue, deep pulse or heavy promptly meets deficiency-weakness of spleen-QI, the Phlegm internal resistance syndrome person, it is all that to meet above-mentioned Western medicine diagnose standard diagnostics be diabetes insulin opposing, meet the tcm diagnosis standard again, carried out diet control, exercise therapy and western medicine are more than two weeks, and the still undesirable person of glycemic control is a MethodsThe cases enrolled.
Get rid of case: (1) has diabetes acute complications person; (2) have acute or the chronic infectious disease person; (3) chronic renal insufficiency, cardiac insufficiency and chronic hepatopathy person are arranged; (4) type 1 diabetes person.
All MethodsThe cases enrolled is given and Drug therapy on diet control, exercise therapy basis.The treatment group: the turbid capsule of QI invigoratingization, each 4, every day 3 times is oral; Matched group: the pioglitazone hydrochloride sheet, each 15mg, every day 1 time is oral.Two groups is a course of treatment with 12 weeks all.
Observe general data (breathing, heart rate, blood pressure, height, body weight), tcm syndrome (variation of tcm clinical practice symptom, sign, picture of the tongue, pulse condition), health giving quality index (fasting glucose, 2 hours after the meal blood glucose, fasting insulin, glycolated hemoglobin, T-CHOL, triglyceride, low density lipoprotein, LDL, high density lipoprotein, insulin sensitivity sex index, steady-state model insulin resistance index), safety indexes (blood, routine urinalysis, liver function, kidney merit, untoward reaction).
The result shows:
Tcm syndrome: the total effective rate of treatment back treatment group traditional Chinese medical science disease curative effect obviously is better than matched group, relatively have between group significant differences (
P＜0.01).Every tcm syndrome is all seen improvement in various degree after treatment group and the treatment of control group.Treatment group fatigue and weakness, the lazy speech of breathing hard, abdominal distension and anorexia, aching and limp, nervous five highly significants uncomfortable in chest of limbs are better than matched group.Thirsty or sticky, two of dizzinesses significantly are better than matched group, see Table 6.
The health giving quality index:
Two groups after treating steady-state model insulin resistance index, fasting insulin all obviously descend, insulin sensitivity sex index obviously raises, more all have before and after the treatment significant differences (
P＜0.01).Treatment front and back difference compares between two groups, there was no significant difference (
P＞0.05).Concrete outcome sees Table 7.
Two groups of fasting glucose after treating, 2 hours after the meal blood glucose, glycolated hemoglobins all obviously descend, more all have before and after the treatment significant differences (
P＜0.01).Every index treatment front and back difference is relatively learned by statistics and is handled between two groups, there was no significant difference (
P＞0.05).Concrete outcome sees Table 8.
Two groups of triglyceride after treating, low density lipoprotein, LDLs all have decline, the treatment before and after more all have significant difference (
P＜0.05).Have after the treatment group T-CHOL treatment remarkable decline (
P＜0.05), compare with matched group, have significant difference (
P＜0.05).Concrete outcome sees Table 9.
Safety indexes: the treatment group has 3 routine patients abdominal discomfort to occur at period in a medicine, stool is rare, transference cure after decrement, and treatment back liver, renal function, blood, routine urinalysis show no obvious abnormalities.
Conclusion: the turbid capsule of QI invigoratingization can effectively improve the type 2 diabetes mellitus insulin resistant and belong to deficiency of both QI and YIN, the every traditional Chinese medical science disease of the turbid mutual knot card person of the stasis of blood.Treatment group tcm symptom, sign after treating are all obviously improved.Treatment group total effective rate is 88.1%, and the matched group total effective rate is 52.9%, and treatment group curative effect obviously is better than matched group, relatively have between group significant differences (
P＜0.01).The treatment group is improved fatigue and weakness, the lazy speech of breathing hard, abdominal distension and anorexia, limbs are aching and limp, nervous five highly significants uncomfortable in chest are better than matched group, thirsty or sticky, dizzy two significantly be better than matched group.The turbid capsule of QI invigoratingization has stronger advantage aspect the tcm syndrome improving in prompting.
Turbid capsule of QI invigoratingization and pioglitazone hydrochloride all can improve the type 2 diabetes mellitus insulin resistant, increase insulin sensitivity, blood sugar lowering, two groups of therapeutic equivalences.Two groups of patients steady-state model insulin resistance index, fasting insulin after treating all obviously descend, insulin sensitivity sex index obviously raises, fasting glucose, 2 hours after the meal blood glucose, glycolated hemoglobin all obviously descend, more all have before and after the treatment significant differences (
P＜0.01).Between two groups before and after the treatment of every index difference relatively, learn by statistics handle there was no significant difference (
P＞0.05).
Turbid capsule of QI invigoratingization and pioglitazone hydrochloride all have the effect that improves patient's metabolism disorder of blood lipid, and aspect hypercholesterolemia reducing, the turbid capsule of QI invigoratingization is better than pioglitazone hydrochloride.Two groups of triglyceride after treating, low density lipoprotein, LDLs all have decline, the treatment before and after more all have significant difference (
P＜0.05).Have after the treatment group T-CHOL treatment remarkable decline (
P＜0.05), compared with matched group significant difference (
P＜0.05).
Claims (3)
1. medicine for the treatment of the type 2 diabetes mellitus insulin resistant is that the crude drug by following parts by weight prepares: 30～40 parts of the Radixs Astragali, 15～20 parts of Rhizoma Polygonatis, 14～18 parts of Rhizoma Coptidis, 15～20 parts of Ramulus Euonymis, 10～15 parts of Bombyx bombycis.
2. one kind prepares the method that claim 1 is treated the medicine of type 2 diabetes mellitus insulin resistant, may further comprise the steps:
A) astragalus membranaceus powder with described 1/2 parts by weight is broken into fine powder, and is standby;
B) get other crude drug and remain the Radix Astragali of 1/2 parts by weight, decoct with water three times, collecting decoction filters, and it is 1.26～1.33 thick paste that filtrate is condensed into 60～85 ℃ of relative densities;
C) in thick paste, add above-mentioned Radix Astragali fine powder, mix homogeneously, drying is pulverized, and obtains medicine activity component.
3. the preparation method of the medicine of treatment type 2 diabetes mellitus insulin resistant according to claim 2 is characterized in that in the described step b), and each amount of water is 8～10 times of weight of medicine total amount, decocts 1～2h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100488897A CN102114185B (en) | 2011-03-02 | 2011-03-02 | Medicament for treating insulin resistance of type 2 diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100488897A CN102114185B (en) | 2011-03-02 | 2011-03-02 | Medicament for treating insulin resistance of type 2 diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102114185A true CN102114185A (en) | 2011-07-06 |
| CN102114185B CN102114185B (en) | 2012-05-23 |
Family
ID=44213185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100488897A Expired - Fee Related CN102114185B (en) | 2011-03-02 | 2011-03-02 | Medicament for treating insulin resistance of type 2 diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102114185B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103621889A (en) * | 2012-08-21 | 2014-03-12 | 李嘉轩 | Blood glucose reduction vermicelli and silk cocoon juice used by the same, and silk cocoon juice preparation method |
| CN104688923A (en) * | 2013-09-09 | 2015-06-10 | 宁波大学 | Medicine used for treating insulin resistance |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1144111A (en) * | 1995-08-25 | 1997-03-05 | 卢正罡 | Shuangjie Jiangtangjing capsule |
| CN1235551A (en) * | 1996-11-01 | 1999-11-17 | 参天堂制药株式会社 | Pharmaceutical composition for diabetes |
-
2011
- 2011-03-02 CN CN2011100488897A patent/CN102114185B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1144111A (en) * | 1995-08-25 | 1997-03-05 | 卢正罡 | Shuangjie Jiangtangjing capsule |
| CN1235551A (en) * | 1996-11-01 | 1999-11-17 | 参天堂制药株式会社 | Pharmaceutical composition for diabetes |
Non-Patent Citations (3)
| Title |
|---|
| 《中医药信息》 20010510 孙明友等 消渴康治疗Ⅱ型糖尿病降糖机理的研究 第18卷, 第03期 2 * |
| 《中成药》 20030625 冯长根等 治疗糖尿病并发症的中药复方制剂 第25卷, 第06期 2 * |
| 《陕西中医》 20090105 莫娜等 中医药治疗2型糖尿病胰岛素抵抗用药分析 第30卷, 第01期 2 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103621889A (en) * | 2012-08-21 | 2014-03-12 | 李嘉轩 | Blood glucose reduction vermicelli and silk cocoon juice used by the same, and silk cocoon juice preparation method |
| CN104688923A (en) * | 2013-09-09 | 2015-06-10 | 宁波大学 | Medicine used for treating insulin resistance |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102114185B (en) | 2012-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102028900B (en) | Traditional Chinese medicine for treating metabolic syndrome and preparation method thereof | |
| CN100493572C (en) | Composition of medication for treating diabetes | |
| CN1108804C (en) | Diabetes treating medicine and its prepn. method | |
| CN102872423B (en) | Traditional Chinese medicine compound for treating glycuresis and preparation method thereof | |
| CN102114185B (en) | Medicament for treating insulin resistance of type 2 diabetes | |
| CN104547530B (en) | A kind of Chinese medicine composition for treating diabetes | |
| CN105596735A (en) | Medicine composition for treating diabetes mellitus | |
| CN105434679A (en) | Traditional Chinese medicine health-care preparation for reducing weight and slimming | |
| CN101843843A (en) | Chinese medicament for treating diabetes | |
| CN102274396B (en) | Traditional Chinese medicine for treating diabetic nephropathy and preparation method thereof | |
| CN109498731A (en) | A kind of tonifying speen and tonifying kidney tune sugar-pill and preparation method thereof for treating diabetes B Pishenqixu syndrome | |
| CN101884760B (en) | Chinese medicinal composition for treating diabetes mellitus and preparation method thereof | |
| CN105663772B (en) | A kind of drug for treating diabetes | |
| CN106729304B (en) | A kind of Chinese medicine for mitigating fasting or side reaction of dieting and preparation method thereof | |
| CN1263488C (en) | Capsule of dual gen-sengs and preparing technique | |
| CN116059302B (en) | Traditional Chinese medicine composition for treating gastrointestinal motility diseases and preparation method and application thereof | |
| CN103230552A (en) | Traditional Chinese medicine for treating diabetes mellitus | |
| CN102366480A (en) | Medicine for treating diabetes and preparation method thereof | |
| CN103181945A (en) | Novel application of luffa seeds | |
| CN105878607A (en) | Traditional Chinese medicine preparation for treating obesity | |
| CN1236795C (en) | Medicinal preparation of traditional Chinese medicine for treating diabetes and its production method | |
| CN105535195A (en) | Traditional Chinese medicine preparation for treating diabetes and preparation method and application thereof | |
| CN102772630B (en) | Medicine for treating type-II diabetes mellitus | |
| CN104189314A (en) | Pharmaceutical composition for treating hyperlipidemia with phlegm and turbid repression syndrome | |
| CN117838771A (en) | Traditional Chinese medicine compound composition for treating T2DM insulin resistance and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120523 Termination date: 20190302 |